Hubei Guangji Pharmaceutical Stock Forum

Despite a recent share price increase, the company's low P/S ratio, likely due to declining revenue and poor industry performance, may continue to limit the share price unless medium-term conditions improve.

Hubei Guangji Pharmaceutical's stock price decline and deteriorating returns over the past year are disappointing. The company's situation echoes Warren Buffett's words, 'turnarounds seldom turn'. The falling EPS and share price indicate a tough outlook.